Journal Watch · Frontiers in Immunology · 2026

Hospital exemption use of virus-specific T-lymphocytes in children: early experience within the Allovista clinical trial framework.

However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.

Ussowicz M, Ślęzak A, Myszka-Kozłowska M et al.Frontiers in Immunology4 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1805803PMID: 42039155Study type: cohort / observational clinical study

TL;DR

However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.

Key findings

  • Despite biological activity, four children died: from progressive EBV disease (n=1), ADV infection (n=1), relapse of HL (n=1) and multi-organ failure with invasive fungal disease in a child with multi-viral infection (n=1).
  • Two patients with complete virological responses are alive with sustained remission of viremia at the last follow-up.
  • No new-onset or worsening aGVHD was documented after VST infusion.<h4>Conclusions</h4>VST administered as an ATMP-HE are feasible in routine clinical practice and demonstrate rapid antiviral activity in heavily pretreated pediatric patients.
  • However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.

Numbers at a glance (from the abstract)

n=180%40%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A single intravenous infusion of 1.01×10<sup>5</sup>-1.85×10<sup>6</sup> VST (median 2.5×10<sup>5</sup>) was administered. Virological response was assessed by quantitative PCR up to 4 weeks post-infusion, acute GVHD (aGVHD) and survival were recorded.<h4>Results</h4>Virological outcomes were evaluable in five patients. Four of five (80%) evaluated patients achieved at least a 1-log reduction in viral load, including two (40%) with complete clearance by week 4 (one EBV, one ADV). Two additional patients had marked but incomplete or transient viral load reductions, one patient showed minimal virological change.

Full abstract (original)

Background: <h4>Background</h4>Adoptive transfer of virus-specific T lymphocytes (VST) is an emerging strategy for refractory viral infections in immunocompromised individuals and is being prospectively evaluated in the ALLOVISTA clinical trial. Here we describe our experience with hospital-exemption advanced therapy medicinal product (ATMP-HE) VST in six pediatric transplant recipients.<h4>Methods</h4>Six children and adolescents (median age 4.5 years, range 2.5-18.5) treated in two Polish centers received VST for refractory viremia after allogeneic hematopoietic stem cell transplantation: adenovirus (ADV) in three cases, EBV-driven disease (EBV/PTLD or HL relapse with EBV reactivation) in three, including one patient with concomitant CMV/EBV/ADV infection. All patients had failed conventional antiviral and/or immunochemotherapy (cidofovir, rituximab, chemotherapy). VST were generated from allo-HSCT or related donors using automated CliniMACS Prodigy Cytokine Capture System (IFN-γ CCS, Miltenyi Biotec) following antigenic stimulation with viral peptide pools and released as ATMP-HE according to the ALLOVISTA protocol.

What they did: A single intravenous infusion of 1.01×10<sup>5</sup>-1.85×10<sup>6</sup> VST (median 2.5×10<sup>5</sup>) was administered. Virological response was assessed by quantitative PCR up to 4 weeks post-infusion, acute GVHD (aGVHD) and survival were recorded.<h4>Results</h4>Virological outcomes were evaluable in five patients. Four of five (80%) evaluated patients achieved at least a 1-log reduction in viral load, including two (40%) with complete clearance by week 4 (one EBV, one ADV). Two additional patients had marked but incomplete or transient viral load reductions, one patient showed minimal virological change.

Results & conclusions: Despite biological activity, four children died: from progressive EBV disease (n=1), ADV infection (n=1), relapse of HL (n=1) and multi-organ failure with invasive fungal disease in a child with multi-viral infection (n=1). Two patients with complete virological responses are alive with sustained remission of viremia at the last follow-up. No new-onset or worsening aGVHD was documented after VST infusion.<h4>Conclusions</h4>VST administered as an ATMP-HE are feasible in routine clinical practice and demonstrate rapid antiviral activity in heavily pretreated pediatric patients. However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1805803 · PubMed 42039155.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. A single intravenous infusion of 1.01×10<sup>5</sup>-1.85×10<sup>6</sup> VST (median 2.5×10<sup>5</sup>) was administered.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1805803. PubMed ID: 42039155. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ussowicz M, Ślęzak A, Myszka-Kozłowska M et al.. Hospital exemption use of virus-specific T-lymphocytes in children: early experience within the Allovista clinical trial framework.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1805803.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/hospital-exemption-use-of-virus-specific-t-lymphocytes-in-children-early-805803/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides